Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
1,347 results
  • Argatroban dosing in obesity. [Journal Article]
  • TRThromb Res 2018 Jan 09; 163:60-63
  • Elagizi S, Davis K
  • CONCLUSIONS: Obese patients require similar median argatroban maintenance doses when compared to non-obese patients. Based on these results argatroban should be dosed using actual body weight regardless of BMI.
  • Anticoagulation Therapies in Children. [Review]
  • PCPediatr Clin North Am 2017; 64(6):1257-1269
  • Young G
  • Venous thromboembolism is occurring with increasing frequency in children resulting in the more widespread use of anticoagulation in pediatrics. Antithrombotic drugs in children can be divided into t...
  • Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. [Multicenter Study]
  • JACCJ Am Coll Cardiol 2017 Nov 28; 70(21):2636-2648
  • Schindewolf M, Steindl J, … Lindhoff-Last E
  • CONCLUSIONS: Fondaparinux is effective and safe in suspected acute HIT; no HIT-specific complications occurred in the fondaparinux-treated patients, even among those with a high clinical HIT probability. Further data from randomized controlled trials are urgently needed because lepirudin was recalled from the market; danaparoid access has been limited and is not approved in the United States; and argatroban is contraindicated in patients with impaired liver function, and activated partial thromboplastin time confounding may interfere with monitoring. (Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II; NCT01304238).
New Search Next